Uncategorized

Collaboration to Improve Access to Study for Alzheimer’s Disease Las Vegas, Nev. – Dec. 23 2025 – Today, Global Alzheimer’s Platform Foundation® (GAP) and Clinical Neurology Specialists (CNS) announced their collaboration to accelerate Alzheimer’s disease research in Las Vegas. CNS has joined the GAP-sponsored study, Bio-Hermes-002, a unique, observational platform study that compares blood-based and digital biomarkers […]

20 Dec ‘It’s the best time’: Family members may notice signs of Alzheimer’s at holiday gatherings Posted at 20:23h in Uncategorized by Belinda Russell 0 Comments ATLANTIS, Fla. — It’s the holiday season and while you celebrate with friends and family some experts say you may also notice some changes in elderly loved ones you haven’t seen for a while. Dr. Linda […]

El sábado 21 de septiembre se lleva a cabo un evento gratuito y en español para informar a la comunidad hispana sobre el Alzheimer y dar consejos de prevención.Author: Yolanda Garcia-Espinoza Published: 5:03 PM PDT September 16, 2024 PHOENIX — La comunidad hispana tiene alto riego de desarrollar alguna enfermedad de demencia y la más común es Alzheimer. […]

Global Alzheimer’s Platform Foundation 2023 National Citizen Scientist Champion Award recipient Jeannie Weiss and Syrentis Clinical Research Vice President/Director of Clinical Operations Dr. Lorrie Bisesi join to discuss Alzheimer’s #octalkradio

The results of the Bio-Hermes study appear in Alzheimer’s & Dementia showing how new Alzheimer’s detecting blood tests perform across a broad range of races and ethnicities for the first time. Washington D.C., Feb. 28, 2024- The Global Alzheimer’s Platform Foundation®, (GAP) is releasing the first results from the Bio-Hermes-001 Study. This study in over […]

GAP-Net Site Brigham and Women’s Hospital Center for Alzheimer Research & Treatment (CART), was featured in their local news station about the importance of volunteer participation in clinical research. A local hospital is now part of a global effort to test a drug that may delay the devastating impact of Alzheimer’s disease. The progressive neurological […]

Experts voice concerns over pre-judging promising treatments in the pipeline Today, five top Alzheimer’s clinicians and researchers called into question the preliminary proposal from the Centers for Medicare and Medicaid Services (CMS) to limit coverage FDA-approved monoclonal antibodies that target amyloid for the treatment of Alzheimer’s disease. The CMS proposal would alter the course of […]

Despite highest incidence of dementia, this is the first-ever Alzheimer’s clinical study in Starr County Rio Grande City, TX (February 2, 2022) –El Faro Health & Therapeutics will begin screening volunteers for its first-ever clinical trial in Rio Grande City, TX. The Bio-Hermes Study, sponsored by the Global Alzheimer’s Platform Foundation® (GAP), seeks volunteers with or […]

GAP President John Dwyer spoke to Pink Sheet about the CMS NCD proposal. The Centers for Medicare and Medicaid Service’s proposal to allow Medicare to pay for amyloid-directed monoclonal antibody drugs for Alzheimer’s only when they are used in randomized controlled clinical trials could significantly curtail access to the drugs for at least four years, […]

Microsoft and Gates Ventures founder, Bill Gates, mentions GAP’s Bio-Hermes study to the World Dementia Council. We’ve all heard the statistics: Today, nearly 55 million people suffer from Alzheimer’s disease or related dementias. According to the WHO, dementia is the fastest growing burden on healthcare systems and the seventh leading cause of death worldwide. Its […]